Balaji Prasad
Stock Analyst at Barclays
(3.09)
# 1,317
Out of 4,761 analysts
140
Total ratings
43.59%
Success rate
0.99%
Average return
Main Sectors:
Stocks Rated by Balaji Prasad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZTS Zoetis | Maintains: Overweight | $242 → $244 | $160.46 | +52.06% | 16 | Feb 14, 2025 | |
| OGN Organon & Co. | Maintains: Overweight | $26 → $24 | $15.49 | +54.94% | 2 | Feb 14, 2025 | |
| PAHC Phibro Animal Health | Maintains: Underweight | $20 → $22 | $22.50 | -2.22% | 8 | Feb 10, 2025 | |
| IDXX IDEXX Laboratories | Maintains: Overweight | $481 → $520 | $452.77 | +14.85% | 9 | Feb 4, 2025 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Overweight | $28 → $26 | $16.74 | +55.32% | 12 | Jan 30, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Overweight | $60 → $62 | $47.84 | +29.60% | 4 | Jan 27, 2025 | |
| EOLS Evolus | Maintains: Overweight | $20 → $22 | $13.99 | +57.26% | 7 | Jan 27, 2025 | |
| LGND Ligand Pharmaceuticals | Maintains: Overweight | $150 → $160 | $120.67 | +32.59% | 15 | Dec 16, 2024 | |
| PCRX Pacira BioSciences | Maintains: Equal-Weight | $25 → $17 | $25.16 | -32.43% | 8 | Nov 12, 2024 | |
| VTRS Viatris | Maintains: Underweight | $11 → $12 | $11.25 | +6.67% | 7 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $19 → $20 | $11.02 | +81.49% | 12 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $17 | $13.35 | +27.34% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $10 | $7.83 | +27.71% | 4 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $18 | $12.28 | +46.58% | 5 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $230 → $200 | $136.01 | +47.05% | 9 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2.5 → $10 | $2.99 | +234.45% | 2 | Oct 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $7 | $1.07 | +554.21% | 7 | Oct 23, 2023 |
Zoetis
Feb 14, 2025
Maintains: Overweight
Price Target: $242 → $244
Current: $160.46
Upside: +52.06%
Organon & Co.
Feb 14, 2025
Maintains: Overweight
Price Target: $26 → $24
Current: $15.49
Upside: +54.94%
Phibro Animal Health
Feb 10, 2025
Maintains: Underweight
Price Target: $20 → $22
Current: $22.50
Upside: -2.22%
IDEXX Laboratories
Feb 4, 2025
Maintains: Overweight
Price Target: $481 → $520
Current: $452.77
Upside: +14.85%
Teva Pharmaceutical Industries
Jan 30, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $16.74
Upside: +55.32%
Tarsus Pharmaceuticals
Jan 27, 2025
Maintains: Overweight
Price Target: $60 → $62
Current: $47.84
Upside: +29.60%
Evolus
Jan 27, 2025
Maintains: Overweight
Price Target: $20 → $22
Current: $13.99
Upside: +57.26%
Ligand Pharmaceuticals
Dec 16, 2024
Maintains: Overweight
Price Target: $150 → $160
Current: $120.67
Upside: +32.59%
Pacira BioSciences
Nov 12, 2024
Maintains: Equal-Weight
Price Target: $25 → $17
Current: $25.16
Upside: -32.43%
Viatris
Nov 8, 2024
Maintains: Underweight
Price Target: $11 → $12
Current: $11.25
Upside: +6.67%
Nov 8, 2024
Maintains: Overweight
Price Target: $19 → $20
Current: $11.02
Upside: +81.49%
Nov 6, 2024
Maintains: Overweight
Price Target: $17 → $17
Current: $13.35
Upside: +27.34%
Aug 13, 2024
Maintains: Overweight
Price Target: $8 → $10
Current: $7.83
Upside: +27.71%
Jul 25, 2024
Maintains: Overweight
Price Target: $22 → $18
Current: $12.28
Upside: +46.58%
May 3, 2024
Maintains: Overweight
Price Target: $230 → $200
Current: $136.01
Upside: +47.05%
Oct 23, 2023
Maintains: Equal-Weight
Price Target: $2.5 → $10
Current: $2.99
Upside: +234.45%
Oct 23, 2023
Maintains: Overweight
Price Target: $8 → $7
Current: $1.07
Upside: +554.21%